EFFICACY OUTCOMES OF PLACEBO MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RESPONDED TO PLACEBO INDUCTION THERAPY: RESULTS FROM THE PHASE 3 COMMAND STUDY

被引：0
|
作者：
Atreya, Raja
Ferrante, Marc
Afzali, Anita
Bamias, Giorgos
Long, Millie D.
Neimark, Ezequiel
Levine, Phillip
Cheng, Ling
Kalabic, Jasmina
Hecht, Patrick
Vladea, Ramona C.
Schreiber, Stefan
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1792
引用
收藏
页码：S815 / S816
页数：2
相关论文
共 50 条
  • [1] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
    Louis, E.
    Panaccione, R.
    Parkes, G.
    Peyrin-Biroulet, L.
    Ferrante, M.
    Hisamatsu, T.
    Siegmund, B.
    Kalabic, J.
    Levine, P.
    Neimark, E.
    Wallace, K.
    Chen, S.
    Cheng, L.
    Duan, W. R.
    Armuzzi, A.
    Biederman, L.
    Loftus, E.
    Melmed, G.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12
  • [2] RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND
    Schreiber, Stefan
    Panaccione, Remo
    Parkes, Gareth C.
    Peyrin-Biroulet, Laurent
    Ferrante, Marc
    Hisamatsu, Tadakazu
    Siegmund, Britta
    Kalabic, Jasmina
    Levine, Phillip
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Cheng, Ling
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward V.
    Melmed, Gil
    Louis, Edouard
    GASTROENTEROLOGY, 2024, 166 (05) : S238 - S238
  • [3] THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
    Rubin, David T.
    Allegretti, Jessica R.
    Panes, Julian
    Shipitofsky, Nicole
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Dignass, Axel
    GASTROENTEROLOGY, 2024, 166 (05) : S180 - S180
  • [4] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
    Allegretti, Jessica R.
    Peyrin-Biroulet, Laurent
    Feagan, Brian G.
    Bressler, Brian
    Lichtenstein, Gary R.
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Shipitofsky, Nicole
    Jiang, Lingjing
    Zhang, Hongyan
    Hisamatsu, Tadakazu
    Panes, Julian
    Dignass, Axel
    Sands, Bruce E.
    Rubin, David T.
    GASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572
  • [5] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Watanabe, Mamoru
    Motoya, Satoshi
    Watanabe, Kenji
    Ogata, Haruhiko
    Kanai, Takanori
    Matsui, Toshiyuki
    Suzuki, Yasuo
    Shikamura, Mitsuhiro
    Igeta, Masataka
    Oda, Kazunori
    Hori, Tetsuharu
    Araki, Takahiro
    Hibi, Toshifumi
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S381
  • [6] EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
    Dubinsky, Marla C.
    Irving, Peter M.
    Li, Xingyuan
    Howaldt, Stefanie
    Pokrotnieks, Juris
    Krueger, Kathryn A.
    Laskowski, Janelle
    Lissoos, Trevor
    Milata, Joe
    Morris, Nathan
    Arora, Vipin
    Milch, Catherine
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S1393 - S1394
  • [7] Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study
    Begun, J.
    Dubinsky, M. C.
    Irving, P. M.
    Li, X.
    Howaldt, S.
    Pokrotnieks, J.
    Krueger, K.
    Laskowski, J.
    Lissoos, T.
    Milata, J.
    Morris, N.
    Arora, V.
    Milch, C.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 133 - 133
  • [8] Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
    Danese, S.
    Vermeire, S.
    Zhou, W.
    Pangan, A.
    Siffledeen, J.
    Hebuterne, X.
    Nakase, H.
    Higgins, P.
    Chen, M. H.
    Sanchez-Gonzalez, Y.
    Huang, B.
    Xie, W.
    Liu, J.
    Weinreich, M.
    Pannaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S022 - S024
  • [9] Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study
    Danese, Silvio
    Vermeire, Severine
    Zhou, Wen
    Pangan, Aileen
    Siffledeen, Jesse
    Hebuterne, Xavier
    Nakase, Hiroshi
    Chen, Minhu
    Higgins, Peter
    Sanchez-Gonzalez, Yuri
    Huang, Bidan
    Xian, Wangang
    Liu, Jianzhong
    Weinreich, Michael
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S312 - S313
  • [10] Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
    Vermeire, Severine
    Danese, Silvio
    Zhou, Wen
    Pangan, Aileen
    Greenbloom, Susan
    D'Haens, Geert
    Panes, Julian
    Juillerat, Pascal
    Lindsay, James
    Loftus, Edward V.
    Sandborn, William
    Reinisch, Walter
    Sanchez-Gonzalez, Yuri
    Huang, Bidan
    Xian, Wangang
    Liu, Jianzhong
    Weinreich, Michael
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S357
12345